• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

宫腔内人工授精联合卵巢刺激与不明原因不孕期待治疗(TUI):一项实用、开放标签、随机、对照、两中心试验。

Intrauterine insemination with ovarian stimulation versus expectant management for unexplained infertility (TUI): a pragmatic, open-label, randomised, controlled, two-centre trial.

机构信息

Department of Obstetrics and Gynaecology, University of Auckland, Auckland, New Zealand; Fertility Plus, Auckland District Health Board, Auckland, New Zealand.

Fertility Plus, Auckland District Health Board, Auckland, New Zealand.

出版信息

Lancet. 2018 Feb 3;391(10119):441-450. doi: 10.1016/S0140-6736(17)32406-6. Epub 2017 Nov 23.

DOI:10.1016/S0140-6736(17)32406-6
PMID:29174128
Abstract

BACKGROUND

Women with unexplained infertility are often offered intrauterine insemination (IUI) with ovarian stimulation as an alternative to in-vitro fertilisation (IVF). However, little evidence exists that IUI is an effective treatment. In 2013, the UK National Institute for Health and Care Excellence recommended that IUI should not be routinely offered for couples with unexplained infertility.

METHODS

For this pragmatic, open-label, randomised, controlled, two-centre study, we enrolled women attending two fertility clinics in New Zealand with unexplained infertility and an unfavourable prognosis of natural conception. Participants were randomly assigned (1:1) using a computer-generated randomisation sequence, prepared by an independent statistician, to either three cycles of IUI with ovarian stimulation (with either oral clomifene citrate [50-150 mg, days 2-6] or oral letrozole [2·5-7·5 mg, days 2-6], with choice of ovarian stimulation made by the clinic) or three cycles of expectant management (couples advised to be sexually active around the likely time of ovulation and provided with a diary to record the first day of each menstrual cycle and dates of sexual activity) in blocks of four, six, and ten, without stratification. The participating couple and the clinicians were informed of treatment allocation. The primary outcome was cumulative livebirth rate in the intention-to-treat population. The safety analyses were done in the intention-to-treat population. This study was prospectively registered with the Australian and New Zealand Clinical Trials Register, number ACTRN12612001025820.

FINDINGS

Between March 12, 2013, and May 12, 2016, we randomly assigned 101 women to IUI with ovarian stimulation and 100 to expectant management, all of whom were included in the primary efficacy analysis and safety analyses. Women assigned to IUI had a higher cumulative livebirth rate than women assigned to expectant management (31 [31%] livebirths among 101 women vs nine [9%] livebirths among 100 women; risk ratio [RR] 3·41, 95% CI 1·71-6·79; p=0·0003). Of 31 livebirths in the IUI group, 23 resulted from IUI cycles and eight were conceived without assistance before or between IUI cycles. Of nine livebirths in the expectant management group, one patient was pregnant from IUI with ovarian stimulation at study entry and one had received off-protocol treatment (IVF). Two sets of twins were born, both in the IUI group (one from a cancelled cycle for over-response).

INTERPRETATION

IUI with ovarian stimulation is a safe and effective treatment for women with unexplained infertility and an unfavourable prognosis for natural conception.

FUNDING

Auckland Medical Research Foundation, Evelyn Bond Fund of Auckland District Health Board, Mercia Barnes Trust of Royal Australian and New Zealand College of Obstetricians and Gynaecologists, Maurice and Phyllis Paykel Trust, and The Nurture Foundation for Reproductive Research.

摘要

背景

对于不明原因不孕的女性,通常会提供宫腔内人工授精(IUI)加卵巢刺激作为体外受精(IVF)的替代方案。然而,目前几乎没有证据表明 IUI 是一种有效的治疗方法。2013 年,英国国家卫生与保健卓越研究所(National Institute for Health and Care Excellence,NICE)建议对于不明原因不孕的夫妇,不应常规提供 IUI。

方法

这是一项务实的、开放性标签、随机、对照、双中心研究,我们招募了新西兰两家生育诊所的不明原因不孕且自然受孕预后不佳的女性。参与者按照 1:1 的比例随机分配(1:1),使用计算机生成的随机序列,由独立的统计学家准备,随机分配至 IUI 加卵巢刺激(口服枸橼酸氯米芬[50-150mg,第 2-6 天]或口服来曲唑[2.5-7.5mg,第 2-6 天],由诊所选择卵巢刺激方案)或期待管理(告知夫妇在可能的排卵时间附近保持性行为活跃,并提供记录每个月经周期的第一天和性行为日期的日记)三组,每组 3 个周期,以 4、6 和 10 个周期为一个块,不进行分层。参与的夫妇和临床医生均被告知治疗分组情况。主要结局是意向治疗人群中的累积活产率。安全性分析在意向治疗人群中进行。该研究在澳大利亚和新西兰临床试验注册中心(Australian and New Zealand Clinical Trials Register)进行了前瞻性注册,编号为 ACTRN12612001025820。

结果

2013 年 3 月 12 日至 2016 年 5 月 12 日,我们随机分配了 101 名女性至 IUI 加卵巢刺激组和 100 名女性至期待管理组,所有女性均纳入主要疗效分析和安全性分析。与期待管理组相比,接受 IUI 治疗的女性累积活产率更高(101 名女性中 31 名活产[31%] vs 100 名女性中 9 名活产[9%];风险比[RR]3.41,95%CI 1.71-6.79;p=0.0003)。在 IUI 组的 31 例活产中,23 例来自 IUI 周期,8 例在 IUI 周期之前或期间未经辅助受孕。在期待管理组的 9 例活产中,1 例患者在研究入组时因卵巢刺激进行了 IUI 后怀孕,1 例患者接受了方案外治疗(IVF)。两组双胞胎均出生于 IUI 组(1 例来自因超反应取消的周期)。

结论

IUI 加卵巢刺激是不明原因不孕且自然受孕预后不佳的女性的一种安全有效的治疗方法。

资金

奥克兰医学研究基金会、奥克兰地区卫生委员会伊芙琳·邦德基金、皇家澳大利亚和新西兰妇产科医师学院默西亚·巴恩斯信托基金、莫里斯和菲利斯·佩尔基金会、以及生育研究基金会。

相似文献

1
Intrauterine insemination with ovarian stimulation versus expectant management for unexplained infertility (TUI): a pragmatic, open-label, randomised, controlled, two-centre trial.宫腔内人工授精联合卵巢刺激与不明原因不孕期待治疗(TUI):一项实用、开放标签、随机、对照、两中心试验。
Lancet. 2018 Feb 3;391(10119):441-450. doi: 10.1016/S0140-6736(17)32406-6. Epub 2017 Nov 23.
2
In vitro fertilisation for unexplained subfertility.不明原因的亚生育力的体外受精。
Cochrane Database Syst Rev. 2015 Nov 19;2015(11):CD003357. doi: 10.1002/14651858.CD003357.pub4.
3
In vitro fertilisation for unexplained subfertility.不明原因的亚生育力的体外受精
Cochrane Database Syst Rev. 2002(2):CD003357. doi: 10.1002/14651858.CD003357.
4
In vitro fertilisation for unexplained subfertility.不明原因的亚生育力的体外受精。
Cochrane Database Syst Rev. 2005 Apr 18(2):CD003357. doi: 10.1002/14651858.CD003357.pub2.
5
Intra-uterine insemination for unexplained subfertility.不明原因的亚生育症的宫腔内人工授精
Cochrane Database Syst Rev. 2020 Mar 3;3(3):CD001838. doi: 10.1002/14651858.CD001838.pub6.
6
In vitro fertilisation for unexplained subfertility.不明原因的亚生育力的体外受精。
Cochrane Database Syst Rev. 2012 Apr 18(4):CD003357. doi: 10.1002/14651858.CD003357.pub3.
7
In vitro fertilisation for unexplained subfertility.不明原因不孕的体外受精。
Cochrane Database Syst Rev. 2023 Sep 27;9(9):CD003357. doi: 10.1002/14651858.CD003357.pub5.
8
Effects of Letrozole-HMG and Clomiphene-HMG on Incidence of Luteinized Unruptured Follicle Syndrome in Infertile Women Undergoing Induction Ovulation and Intrauterine Insemination: A Randomised Trial.来曲唑-人绝经期促性腺激素与克罗米芬-人绝经期促性腺激素对接受诱导排卵和宫内人工授精的不孕女性黄素化未破裂卵泡综合征发生率的影响:一项随机试验
Glob J Health Sci. 2015 Sep 1;8(4):244-52. doi: 10.5539/gjhs.v8n4p244.
9
Randomized controlled trial comparing superovulation with letrozole versus recombinant follicle-stimulating hormone combined with intrauterine insemination for couples with unexplained infertility who had failed clomiphene citrate stimulation and intrauterine insemination.一项随机对照试验,比较来曲唑超促排卵与重组促卵泡激素联合宫腔内人工授精,用于既往枸橼酸氯米芬刺激及宫腔内人工授精失败的不明原因不孕夫妇。
Fertil Steril. 2008 Sep;90(3):678-83. doi: 10.1016/j.fertnstert.2007.06.099. Epub 2007 Oct 25.
10
Interventions for unexplained infertility: a systematic review and network meta-analysis.不明原因不孕症的干预措施:一项系统评价和网状Meta分析
Cochrane Database Syst Rev. 2019 Sep 5;9(9):CD012692. doi: 10.1002/14651858.CD012692.pub2.

引用本文的文献

1
Comparative analysis of cumulative live birth rates in patients with recurrent pregnancy loss undergoing preimplantation genetic testing for aneuploidy versus conventional in vitro fertilisation/intracytoplasmic sperm injection: a retrospective study.复发性流产患者接受非整倍体植入前基因检测与传统体外受精/卵胞浆内单精子注射的累积活产率比较分析:一项回顾性研究
J Ovarian Res. 2025 Jul 3;18(1):141. doi: 10.1186/s13048-025-01721-3.
2
Progesterone Luteal Support in Natural Cycles for Unexplained Infertility: A Randomised Controlled Trial (The PiNC Trial).自然周期中孕激素黄体支持治疗不明原因不孕症:一项随机对照试验(PiNC试验)
BJOG. 2025 Aug;132(9):1220-1227. doi: 10.1111/1471-0528.18171. Epub 2025 Apr 21.
3
Causal Multistate Models to Evaluate Treatment Delay.
用于评估治疗延迟的因果多状态模型
Stat Med. 2025 Mar 30;44(7):e70061. doi: 10.1002/sim.70061.
4
Prognosis-based management of unexplained infertility-why not?基于预后的不明原因不孕症管理——为何不呢?
Hum Reprod Open. 2024 Mar 22;2024(2):hoae015. doi: 10.1093/hropen/hoae015. eCollection 2024.
5
Impact of current and previous sperm findings on outcomes of intrauterine insemination.当前及既往精子检查结果对宫腔内人工授精结局的影响。
Reprod Med Biol. 2024 Apr 8;23(1):e12574. doi: 10.1002/rmb2.12574. eCollection 2024 Jan-Dec.
6
The relationship between duration of infertility and clinical outcomes of intrauterine insemination for younger women: a retrospective clinical study.不孕时间与年轻女性宫腔内人工授精临床结局的关系:一项回顾性临床研究。
BMC Pregnancy Childbirth. 2024 Mar 14;24(1):199. doi: 10.1186/s12884-024-06398-y.
7
Safety of Plasma Rich in Growth Factors (PRGF) as additive to healthy human sperm samples: a pilot study.富含生长因子的血浆(PRGF)作为添加剂用于健康人精子样本的安全性:一项初步研究。
JBRA Assist Reprod. 2024 Jun 1;28(2):224-233. doi: 10.5935/1518-0557.20230075.
8
Should IUI replace IVF as first-line treatment for unexplained infertility? A literature review.是否应该将 IUI 替代 IVF 作为不明原因不孕的一线治疗方法?文献回顾。
BMC Womens Health. 2023 Oct 27;23(1):557. doi: 10.1186/s12905-023-02717-1.
9
Association between follicle size, endometrial thickness, and types of ovarian stimulation (Clomiphene citrate and Letrozole) with biochemical pregnancy rate in women undergone intrauterine insemination.在接受宫腔内人工授精的女性中,卵泡大小、子宫内膜厚度和卵巢刺激类型(枸橼酸氯米酚和来曲唑)与生化妊娠率的关系。
BMC Res Notes. 2023 Oct 24;16(1):286. doi: 10.1186/s13104-023-06529-2.
10
The effect of sperm DNA fragmentation on in vitro fertilization outcomes of unexplained infertility.精子 DNA 碎片化对不明原因不孕的体外受精结局的影响。
Clinics (Sao Paulo). 2023 Jul 27;78:100261. doi: 10.1016/j.clinsp.2023.100261. eCollection 2023.